C Cure 709
Alternative Names: C-709; C-Cure 709; Genetically modified cytotoxic T lymphocyte - CellCureLatest Information Update: 16 Jul 2016
At a glance
- Originator CellCure A/S
- Class Antineoplastics
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Malignant-melanoma in Denmark (Intratumoural, Injection)
- 15 Feb 2006 Final results from a phase I clinical trial in patients with metastatic Melanoma have been added to the adverse events and Cancer therapeutic trials sections